Cardlytics Stock-Based Compensation Growth & History (CDLX)
Cardlytics's stock-based compensation was $28.1M for fiscal 2025.
View full Cardlytics company overviewCardlytics annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $28.1M | −$12.2M | −30.32% |
| 2024 | 2024-12-31 | $40.4M | −$613,000 | −1.50% |
| 2023 | 2023-12-31 | $41.0M | −$3.7M | −8.29% |
| 2022 | 2022-12-31 | $44.7M | −$5.6M | −11.10% |
| 2021 | 2021-12-31 | $50.3M | $17.9M | +55.15% |
| 2020 | 2020-12-31 | $32.4M | $16.5M | +104.38% |
| 2019 | 2019-12-31 | $15.9M | −$10.9M | −40.83% |
| 2018 | 2018-12-31 | $26.8M | $21.6M | +420.50% |
| 2017 | 2017-12-31 | $5.1M | $1.7M | +49.32% |
| 2016 | 2016-12-31 | $3.4M | — | — |
Cardlytics quarterly stock-based compensation
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $2.4M | −$5.1M | −68.60% |
| Q1 2026 | 2026-03-31 | $4.8M | −$3.9M | −44.47% |
| Q4 2025 | 2025-12-31 | $5.5M | −$3.2M | −36.45% |
| Q3 2025 | 2025-09-30 | $6.4M | −$1.6M | −20.37% |
| Q2 2025 | 2025-06-30 | $7.5M | −$5.1M | −40.68% |
| Q1 2025 | 2025-03-31 | $8.7M | −$2.3M | −20.86% |
| Q4 2024 | 2024-12-31 | $8.7M | −$2.4M | −21.33% |
| Q3 2024 | 2024-09-30 | $8.1M | −$2.2M | −21.31% |
| Q2 2024 | 2024-06-30 | $12.6M | $905,000 | +7.71% |
| Q1 2024 | 2024-03-31 | $11.0M | $3.0M | +37.86% |
| Q4 2023 | 2023-12-31 | $11.0M | −$1.5M | −11.75% |
| Q3 2023 | 2023-09-30 | $10.2M | $4.5M | +77.72% |
| Q2 2023 | 2023-06-30 | $11.7M | −$1.1M | −8.59% |
| Q1 2023 | 2023-03-31 | $8.0M | −$5.6M | −41.35% |
| Q4 2022 | 2022-12-31 | $12.5M | −$357,000 | −2.78% |
| Q3 2022 | 2022-09-30 | $5.8M | −$11.1M | −65.73% |
| Q2 2022 | 2022-06-30 | $12.8M | −$495,000 | −3.71% |
| Q1 2022 | 2022-03-31 | $13.6M | $6.3M | +87.43% |
| Q4 2021 | 2021-12-31 | $12.8M | $5.3M | +69.40% |
| Q3 2021 | 2021-09-30 | $16.8M | $5.3M | +45.36% |
| Q2 2021 | 2021-06-30 | $13.3M | $4.2M | +46.43% |
| Q1 2021 | 2021-03-31 | $7.2M | $3.1M | +75.71% |
| Q4 2020 | 2020-12-31 | $7.6M | $4.0M | +111.58% |
| Q3 2020 | 2020-09-30 | $11.6M | $4.1M | +54.66% |
| Q2 2020 | 2020-06-30 | $9.1M | $6.0M | +196.48% |
| Q1 2020 | 2020-03-31 | $4.1M | $2.4M | +141.51% |
| Q4 2019 | 2019-12-31 | $3.6M | −$6.2M | −63.50% |
| Q3 2019 | 2019-09-30 | $7.5M | $1.8M | +30.81% |
| Q2 2019 | 2019-06-30 | $3.1M | −$5.3M | −63.19% |
| Q1 2019 | 2019-03-31 | $1.7M | −$1.2M | −41.10% |
| Q4 2018 | 2018-12-31 | $9.8M | $8.4M | +582.08% |
| Q3 2018 | 2018-09-30 | $5.7M | $4.2M | +286.17% |
| Q2 2018 | 2018-06-30 | $8.3M | $7.1M | +571.90% |
| Q1 2018 | 2018-03-31 | $2.9M | $1.9M | +195.02% |
| Q4 2017 | 2017-12-31 | $1.4M | — | — |
| Q3 2017 | 2017-09-30 | $1.5M | — | — |
| Q2 2017 | 2017-06-30 | $1.2M | — | — |
| Q1 2017 | 2017-03-31 | $983,000 | — | — |
Cardlytics stock-based compensation trends
Over the last five fiscal years, Cardlytics's stock-based compensation decreased from $32.4M to $28.1M, a change of −$4.3M. The latest reported quarter, Q2 2026, shows $2.4M.
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Cardlytics source filings ↗